亚太风湿病联盟关于系统性红斑狼疮管理的共识声明
亚太风湿病联盟针对亚太地区SLE患者制定了首套共识推荐,通过文献回顾与改良德尔菲法形成34条推荐。推荐强调缓解或低疾病活动度为目标、所有亚洲SLE患者使用羟氯喹、主要器官受累行诱导与维持免疫抑制治疗,难治或危及生命时使用生物制剂等,并建议华法林优于直接口服抗凝药用于高风险抗磷脂抗体谱相关血栓事件。
要点
- SLE治疗目标为缓解,不能达到时以低疾病活动度为目标。
- 所有亚洲SLE患者推荐使用羟氯喹,并应筛查肾脏疾病。
- 主要器官受累采用诱导后维持免疫抑制,难治或危及生命时考虑生物制剂等。
核心结论
- 亚太风湿病联盟制定了34条SLE管理共识推荐,强调缓解或低疾病活动度为目标、所有亚洲患者使用羟氯喹、主要器官受累行诱导与维持治疗,难治或危及生命时使用生物制剂等。
研究设计与样本
- 由13名风湿病学家组成核心小组通过面对面会议和电话会议起草声明,对每条声明进行文献回顾以分级证据质量和推荐强度,随后招募29名独立专家和3名SLE患者通过在线投票平台进行改良德尔菲流程达成共识。
主要发现
- 专家组同意SLE患者应转诊至专科医生,通过医患共同决策制定治疗计划。
- 专家组同意缓解是治疗目标,当无法达到缓解时应以低疾病活动度状态为目标。
- 患者应筛查肾脏疾病,所有亚洲SLE患者推荐使用羟氯喹。
- SLE主要器官表现应使用诱导免疫抑制后维持治疗,选项包括环磷酰胺、霉酚酸酯、硫唑嘌呤和钙调神经磷酸酶抑制剂,联合糖皮质激素。
- 生物制剂、联合方案、血浆置换和静脉免疫球蛋白应保留用于难治性或危及生命的疾病。
关键数值与推荐
- 共形成34条共识推荐。
- 对于与高风险抗磷脂抗体谱相关的血栓栓塞性SLE表现,抗凝治疗优先选择华法林而非直接口服抗凝药。
临床怎么用
- 临床中应将SLE患者转诊至专科,通过共同决策制定治疗计划,并以缓解或低疾病活动度为目标。
- 对所有亚洲SLE患者使用羟氯喹,并筛查肾脏疾病。
- 主要器官受累时采用诱导免疫抑制后维持治疗,方案包括环磷酰胺、霉酚酸酯、硫唑嘌呤或钙调神经磷酸酶抑制剂联合糖皮质激素。
- 难治性或危及生命时使用生物制剂、联合方案、血浆置换或静脉免疫球蛋白。
- 高风险抗磷脂抗体谱相关血栓栓塞事件时优先使用华法林而非直接口服抗凝药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Systemic lupus erythematosus (SLE) is prevalent in Asia and carries a variable prognosis among patients across the Asia-Pacific region, which could relate to access to health care, tolerability of medications, and adherence to therapies. Because many aspects of SLE are unique among patients from this region, the Asia-Pacific League of Associations for Rheumatology developed the first set of consensus recommendations on the management of SLE. A core panel of 13 rheumatologists drafted a set of statements through face-to-face meeting and teleconferences. A literature review was done for each statement to grade the quality of evidence and strength of recommendation. 29 independent specialists and three patients with SLE were then recruited for a modified Delphi process to establish consensus on the statements through an online voting platform. A total of 34 consensus recommendations were developed. Panellists agreed that patients with SLE should be referred to a specialist for the formulation of a treatment plan through shared decision making between patients and physicians. Remission was agreed to be the goal of therapy, but when it cannot be achieved, a low disease activity state should be aimed for. Patients should be screened for renal disease, and hydroxychloroquine is recommended for all Asian people with SLE. Major organ manifestations of SLE should be treated with induction immunosuppression and subsequently maintenance; options include cyclophosphamide, mycophenolate mofetil, azathioprine, and calcineurin inhibitors, in combination with glucocorticoids. Biologics, combination regimens, plasma exchange, and intravenous immunoglobulins should be reserved for cases of refractory or life-threatening disease. Anticoagulation therapy with warfarin is preferred to the direct oral anticoagulants for thromboembolic SLE manifestations associated with a high-risk antiphospholipid antibody profile.
引用
- Mok CC, Hamijoyo L, Kasitanon N, et al. The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosus. Lancet Rheumatol. 2021. PMID: 38279404. doi:10.1016/S2665-9913(21)00009-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。